Average Price Target: $30.86
▲ +306.55% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for ProQR Therapeutics in the last 3 months. The average price target is $30.86, with a high forecast of $44.00 and a low forecast of $20.00. The average price target represents a 306.55% upside from the last price of $7.59.
The current consensus among 6 polled investment analysts is to buy stock in ProQR Therapeutics. This Buy consensus rating has held steady for over two years.
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It is primarily developing sepofarsen that is in phase II/III illuminate trial for treating leber's congenital amaurosis 10 disease; QR-421a, which is in phase I/II stellar trial for usher syndrome type 2 and non-syndromic retinitis pigmentosa; QR-1123 that is in phase I/II aurora trial for the treatment of autosomal dominant retinitis pigmentosa; and QR-504a, which is in first clinical trial for the treatment of fuchs endothelial corneal dystrophy. It has a license agreement with Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center. ProQR Therapeutics N.V. was incorporated in 2012 and is headquartered in Leiden, the Netherlands.